Project Manager
Kairat Tabynov Academic degree, title: PhD, associate professor Scopus Author ID: 57196167800 Researcher ID: N-8761-2017 ORCID: 0000-0001-9411-7952
About the project
Relevance
The project aims to obtain and test two novel methods in the immunotherapy of allergic rhinitis and bronchial asthma caused by wormwood pollen (one of the top 10 global aeroallergens). The first approach involves the use of monoclonal antibodies administered intranasally, including in combination with micro/nanoparticles that can potentially competitively block allergen binding to IgE in nasal mucosa. In the second method, allergen-blocking monoclonal antibodies will be combined with the previously developed allergy vaccine PollenVax to achieve the best efficacy. In addition, a pilot development phase is planned in the creation of the PollenVax vaccine, which will bring the development to Technology Readiness Level 6 (TRL-6) on the NASA-BIRAC scale for the biotechnology field.
The purpose of the project
Development of a novel method for immunotherapy of allergic rhinitis and bronchial asthma caused by wormwood pollen, as well as conducting a pilot phase in the development of the previously obtained allergy vaccine PollenVax.
Expected and achieved results
Hypothesis of efficacy of intranasal immunotherapy of wormwood pollen caused allergic rhinitis and bronchial asthma based on monoclonal antibodies, which in native or encapsulated in chitosan nano/microparticles formulations can competitively block allergen binding to IgE antibodies on mucosa of upper airways, will be tested in vivo for the first time.
A novel combined immunotherapy approach for allergic rhinitis and bronchial asthma will be tested involving the use of allergen-blocking monoclonal antibodies and the previously developed Art v 1 (recombinant wormwood pollen major protein)-based vaccine with the oil adjuvant ISA-51 called PollenVax. This approach has the potential to increase the effectiveness of ASIT.
The pilot development phase in the creation of PollenVax vaccine for immunotherapy of wormwood pollen caused allergic rhinitis and bronchial asthma, which includes preparation of laboratory regulations for production, validation of technological process, as well as evaluation of the stability of the drug will be carried out. This work will bring the development to NASA's Technology Readiness Level 6 (TRL-6) according to the BIRAC scale for the biotechnology field (vaccines), and subsequently attract investments for its commercialization.
Project work is aimed at implementing one of the objectives of the Concept for Healthcare Development of the Republic of Kazakhstan until 2026 (Section 5, paragraph 2.2.) on "creating a national vaccine for specific immunotherapy of wormwood allergic rhinitis using recombinant molecules to improve the quality of immunological medical care," and therefore appears strategically important for the country.
The project corresponds to the world trends and can make a significant contribution to the development of allergic science. The project research results will have an enormous impact on increasing the scientific and technical potential and competitiveness of the scientific organization and scientists. In perspective, the project can contribute to the improvement of allergy service and the quality of life of people with allergies. The project will train at least one PhD or master's student in allergology, vaccinology or biotechnology.
Potential consumers of the project results are public and private medical organizations that provide ASIT services.
The results of the project will be disseminated to potential users, communities of scholars, and the public through publications in leading international journals, reports at national and international conferences, and by posting information on the university website and social media (Facebook, LinkedIn).
At least one (1) paper or review article will be published in a peer-reviewed scientific journal indexed in the Science Citation Index Expanded, included in the 1 (first) quartile by impact factor in Web of Science and (or) having a CiteScore percentile in Scopus of at least 80 (eighty), and one patent application for invention will be filed during the entire term of the project.
Achievement of expected results in the process.
Information for potential users
The project aims to solve the global problem - immunotherapy of IgE-mediated allergic diseases occurring in every third inhabitant of the planet [33], using new approaches. Consequently, the project corresponds to the world trends and can become a breakthrough for the development of allergy field of science. The results of the project research will have an enormous impact on increasing the scientific and technical potential and competitiveness of the scientific organization and scientists. The project will train highly qualified specialists in the field of allergology, vaccinology and biotechnology. It is important to note that this project is aimed at solving one of the tasks of the Concept for Health Care Development of the Republic of Kazakhstan until 2026 (Section 5, paragraph 2.2.) on "creation of national vaccine for specific immunotherapy of wormwood allergic rhinitis using recombinant molecules to improve the quality of immunological medical care", and thus meets the national interests of the country.
Members of the research group
Kaissar Tabynov
Academic degree, title: PhD, Professor
Scopus Author ID: 55489111500
Researcher ID: J-4155-2015
ORCID: 0000-0001-5823-1280
Tair Nurpeisov
Academic degree, title: Doctor of Medicine, Associate Professor
Scopus Author ID: 57021908400
Researcher ID: DWS-4156-2022
ORCID: 0000-0002-9590-8905
Meruyert Babayeva
Academic degree, title: No (PhD-student)
Scopus Author ID: 57470636000
Researcher ID: ELB-9536-2022
ORCID: 0000-0001-8694-5942
Guliza Rakhmattulayeva
Academic degree, title: No (PhD-student)
Scopus Author ID: 57219023990
Researcher ID: no
ORCID: 0000-0002-6715-2397
Gleb Fomin
Academic degree, title:No (PhD-student)
Scopus Author ID: 57471475300
Researcher ID: EWV-1048-2022
ORCID: 0000-0002-3242-3898